JNJ - Health Care Company Johnson & Johnson Announces Merger With Ambrx Biopharma | Benzinga
Johnson & Johnson (NYSE:JNJ) has announced a merger with Ambrx Biopharma (NASDAQ:AMAM) that is expected to be completed 2024-H1.
Under the terms of the agreement, Johnson & Johnson has agreed to give Ambrx Biopharma $2.00 billion in cash in exchange for AMAM stock.
About The Companies Involved
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer.
Ambrx Biopharma Inc is a clinical-stage biologics company ...